---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Clinical trials questions"
description: "Clinical trials questions on Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How was the Enhertu DESTINY-Breast06 trial designed? What is Enhertu PFS vs chemotherapy in HR-positive HER2-low breast cancer (DESTINY-Breast06)? What is the response rate with Enhertu in HER2-low breast cancer (DESTINY-Breast06)? What were the Enhertu DESTINY-Breast06 results by HER2 group? 7 further questions follow. 11 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Clinical trials questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)

Questions that apply to every indication of Enhertu are on [Enhertu (fam-trastuzumab deruxtecan-nxki), all indications](https://www.evicenter.com/medical-information/enhertu).

## Clinical trials

<a id="enhertu-destiny-breast06-design"></a>

### How was the Enhertu DESTINY-Breast06 trial designed?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “A Phase 3, international, randomized, open-label trial designed to evaluate ENHERTU vs chemotherapy in eligible patients with HR+/HER2-low and HER2-ultralow mBC<sup>1-4</sup>
> Primary endpoint<sup>1</sup>
> PFS (assessed by BICR) in the HER2-low population”

Source: [ENHERTU: DESTINY-Breast06 Trial, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/destiny-breast-06#:~:text=A%20Phase%203%2C%20international%2C%20randomized%2C,BICR%29%20in%20the%20HER2%2Dlow%20population)

> “Patients 
> were eligible if they had disease progression on (a) at least 2 lines of endocrine 
> therapy in the metastatic setting or (b) one line of endocrine therapy in the metastatic 
> setting and demonstrated progression within 24 months of the start of adjuvant 
> endocrine therapy, or within 6 months of starting first line endocrine therapy  
> in combination with a CDK 4/6 inhibitor in the metastatic setting. Patients with  
> prior chemotherapy in the neoadjuvant or adjuvant setting were eligible if they 
> had a disease-free interval greater than 12 months. The study excluded patients 
> with prior chemotherapy for advanced or metastatic disease, patients with a 
> history of ILD/pneumonitis requiring treatment with steroids or ILD/pneumonitis 
> at screening, uncontrolled or significant cardiovascular disease, untreated and 
> symptomatic brain metastases, or ECOG performance status >1.”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

> “Patients were randomized to receive either ENHERTU 5.4 mg/kg (N=436) by 
> intravenous infusion every three weeks or physician’s choice of single agent 
> chemotherapy (N=430, capecitabine 60%, nab-paclitaxel 24%, or paclitaxel 16%). 
> Randomization was stratified by prior CDK4/6 inhibitor use (yes or no), prior 
> taxane use in the non-metastatic setting (yes or no), and HER2 IHC status of tumor 
> samples (IHC 2+/ISH- vs IHC 1+ vs IHC 0 with membrane staining). Treatment 
> with ENHERTU was administered until disease progression, death, withdrawal of 
> consent, or unacceptable toxicity.”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

<a id="enhertu-destiny-breast04-design"></a>

### How was the Enhertu DESTINY-Breast04 trial designed?

Applies to: Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

> “The efficacy of ENHERTU was evaluated in study DESTINY-Breast04 (NCT03734029), 
> a randomized, multicenter, open-label study that enrolled 557 adult patients with 
> unresectable or metastatic HER2-low breast cancer. The study included 2 cohorts: 
> 494 hormone receptor-positive (HR+) patients and 63 hormone receptor-negative 
> (HR-) patients. HER2-low expression was defined as IHC 1+ or IHC 2+/ISH-, as 
> determined at a central laboratory using Ventana’s PATHWAY anti-HER-2/neu 
> (4B5) Rabbit Monoclonal Primary Antibody assay. Patients must have received 
> chemotherapy in the metastatic setting or have developed disease recurrence 
> during or within 6 months of completing adjuvant chemotherapy. Patients who 
> were HR+ must have received at least one endocrine therapy or be ineligible for 
> endocrine therapy. Patients were randomized 2:1 to receive either ENHERTU 
> 5.4 mg/kg (N=373) by intravenous infusion every 3 weeks or physician’s choice 
> of chemotherapy (N=184, eribulin, capecitabine, gemcitabine, nab paclitaxel, or 
> paclitaxel). Randomization was stratified by HER2 IHC status of tumor samples 
> (IHC 1+ or IHC 2+/ISH-), number of prior lines of chemotherapy in the metastatic 
> setting (1 or 2), and HR status/prior CDK4/6i treatment (HR+ with prior CDK4/6 
> inhibitor treatment, HR+ without prior CDK4/6 inhibitor treatment, or HR-). Treatment 
> was administered until disease progression, death, withdrawal of consent, or  
> unacceptable toxicity. The study excluded patients with a history of ILD/pneumonitis 
> requiring treatment with steroids or ILD/pneumonitis at screening and clinically 
> significant cardiac disease. Patients were also excluded for untreated or symptomatic 
> brain metastases or ECOG performance status >1.”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

> “The major efficacy outcome measure was PFS in patients with HR+ breast cancer 
> assessed by BICR based on RECIST v1.1. Additional efficacy outcome measures 
> were PFS assessed by BICR based on RECIST v1.1 in the overall population (all 
> randomized HR+ and HR- patients), OS in HR+ patients, and OS in the overall 
> population.”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

> “In the control arm, 51.1% of patients received eribulin, 20.1% received capecitabine, 10.3% received nab-paclitaxel, 10.3% received gemcitabine, and 8.2% received paclitaxel.<sup>5</sup>”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=In%20the%20control%20arm%2C%2051.1%25,received%20gemcitabine%2C%20and%208.2%25%20received)

Note: Control-arm proportions are as stated on the Enhertu DESTINY-Breast04 page, for the physician's choice chemotherapy arm.

## Study results

<a id="enhertu-destiny-breast06-pfs-her2-low"></a>

### What is Enhertu PFS vs chemotherapy in HR-positive HER2-low breast cancer (DESTINY-Breast06)?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “In patients with HR+/HER2-low (IHC 1+ or IHC 2+/ISH–) mBC”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=In%20patients%20with%20HR%2B%2FHER2%2Dlow%20%28IHC%201%2B%20or%20IHC%202%2B%2FISH%E2%80%93%29%20mBC)

> “ENHERTU provided 13.2 months median PFS vs 8.1 months with chemotherapy”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=ENHERTU%20provided%2013.2%20months%20median%20PFS%20vs%208.1%20months%20with%20chemotherapy)

> “38% reduction in the risk of disease progression or death with ENHERTU (HR=0.62, 95% CI: 0.52, 0.75; P<0.0001)<sup>1,a</sup>”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=38%25%20reduction%20in%20the%20risk,%28HR%3D0.62%2C%2095%25%20CI%3A%200.52%2C%200.75%3B)

> “Based on stratified analysis with stratification factors prior CDK4/6 inhibitor use (yes vs no) and HER2 IHC status of tumor samples (IHC 1+ vs IHC 2+/ISH–).”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=Based%20on%20stratified%20analysis%20with,%28IHC%201%2B%20vs%20IHC%202%2B%2FISH%E2%80%93%29.)

> “Primary endpoint<sup>1</sup>
> PFS (assessed by BICR) in the HER2-low population”

Source: [ENHERTU: DESTINY-Breast06 Trial, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/destiny-breast-06#:~:text=Primary,BICR%29%20in%20the%20HER2%2Dlow%20population)

> “In the control arm, 60% of patients received capecitabine, 24% nab-paclitaxel, and 16% paclitaxel.”

Source: [ENHERTU: DESTINY-Breast06 Trial, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/destiny-breast-06#:~:text=In%20the%20control%20arm%2C%2060%25,24%25%20nab%2Dpaclitaxel%2C%20and%2016%25%20paclitaxel.)

Note: Median progression-free survival (PFS) by blinded independent central review at the PFS final analysis, the primary endpoint, in the HR-positive HER2-low cohort of DESTINY-Breast06 (ENHERTU n=359, chemotherapy n=354). Patients had progressed on endocrine therapy in the metastatic setting and had not received chemotherapy for metastatic disease. The comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; the control-arm proportions apply to the overall study population.

<a id="enhertu-destiny-breast06-response-her2-low"></a>

### What is the response rate with Enhertu in HER2-low breast cancer (DESTINY-Breast06)?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “Table 32: Efficacy Results in DESTINY-Breast06
> Efficacy 
> Parameter
> HER2-low
> Overall Population
> (HER2-low and HER2-ultralow)
> ENHERTU 
> (N=359)
> Chemotherapy
> (N=354)
> ENHERTU
> (N=436)
> Chemotherapy
> (N=430)”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

> “Confirmed Objective Response Rate (ORR) per BICR<sup>c</sup>
> N
> 326
> 324
> 393
> 389
> n (%) 
> 202 (62.0) 
> 114 (35.2) 
> 246 (62.6)
> 134 (34.4)
> 95% CI 
> 56.5, 67.3 
> 30.0, 40.7
> 57.6, 67.4
> 29.7, 39.4
> Complete 
> Response n (%) 
> 9 (2.8)
> 0
> 10 (2.5)
> 0
> Partial Response 
> n (%) 
> 193 (59.2)
> 114 (35.2)
> 236 (60.1)
> 134 (34.4)
> Duration of Response (DOR) per BICR<sup>c</sup>
> Median, months 
> (95% CI) 
> 14.1  
> (11.9, 15.9)
> 8.6  
> (6.7, 11.3)
> 14.3  
> (12.5, 15.9)
> 8.6  
> (6.9, 11.5)”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

> “<sup>c</sup>	Analysis was performed based on the patients with measurable disease assessed by 
> BICR at baseline.”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

> “ORR and DOR were not tested for statistical significance and were not powered to show differences between treatment arms. Therefore, the clinical significance of these data cannot be determined”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=ORR%20and%20DOR%20were%20not,these%20data%20cannot%20be%20determined)

Note: Table 32 columns, in order: HER2-low cohort ENHERTU (N=359) and chemotherapy (N=354), then the overall population (HER2-low and HER2-ultralow) ENHERTU (N=436) and chemotherapy (N=430). Response rates use patients with measurable disease at baseline (N in the first row), at the PFS final analysis. Patients had progressed on endocrine therapy in the metastatic setting and had not received chemotherapy for metastatic disease. The comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel.

<a id="enhertu-destiny-breast06-overall-population"></a>

### What were the Enhertu DESTINY-Breast06 results by HER2 group?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “Summary of DESTINY-Breast06 efficacy results by patient population<sup>1,2</sup>
> 	Overall study
> population
> (N=866)	HER2-low cohort
> (n=713)	Exploratory HER2-
> ultralow cohort
> (n=153)
> 	ENHERTU
> (n=436)	Chemo-
> therapy
> (n=430)	ENHERTU
> (n=359)	Chemo-
> therapy
> (n=354)	ENHERTU
> (n=77)	Chemo-
> therapy
> (n=76)
> mPFS (mo)
> (95% CI)	13.2
> (12.0, 15.2)	8.1
> (7.0, 9.0)	13.2
> (11.4, 15.2)	8.1
> (7.0, 9.0)	15.1
> (10.0, 17.3)	8.3
> (5.8, 15.2)
> HR (95% CI;
> P value)	0.64
> (0.54, 0.76; P<0.0001)<sup>a</sup>	0.62
> (0.52, 0.75; P<0.0001)<sup>b</sup>	0.76
> (0.49, 1.17)
> ORR
> (n; 95% CI)<sup>c</sup>	62.6%
> (246/393;
> 57.6, 67.4)	34.4%
> (134/389;
> 29.7, 39.4)	62%
> (202/326;
> 56.5, 67.3)	35.2%
> (114/324;
> 30.0, 40.7)	65.7%
> (44/67; 53.1,
> 76.8)	30.8%
> (20/65; 19.9,
> 43.4)”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=Summary%20of%20DESTINY%2DBreast06%20efficacy%20results,43.4%29)

> “The HER2-ultralow cohort was an exploratory population. The data are descriptive and were not tested for statistical significance, nor powered to show a difference between treatment arms. Therefore, the clinical significance of these data cannot be determined”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=The%20HER2%2Dultralow%20cohort%20was%20an,these%20data%20cannot%20be%20determined)

> “ORR was not tested for statistical significance and was not powered to show differences between treatment arms. Therefore, the clinical significance of these data cannot be determined”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=ORR%20was%20not%20tested%20for,these%20data%20cannot%20be%20determined)

> “Based on unstratified analysis.”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=Based%20on%20unstratified%20analysis.)

> “Based on stratified analysis with stratification factors prior CDK4/6 inhibitor use (yes vs no) and HER2 IHC status of tumor samples (IHC 1+ vs IHC 2+/ISH–).”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=Based%20on%20stratified%20analysis%20with,%28IHC%201%2B%20vs%20IHC%202%2B%2FISH%E2%80%93%29.)

> “Analysis was performed based on the patients with measurable disease assessed by BICR at baseline.”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=Analysis%20was%20performed%20based%20on,assessed%20by%20BICR%20at%20baseline.)

Note: Table columns, in order: overall study population ENHERTU and chemotherapy, HER2-low cohort ENHERTU and chemotherapy, and exploratory HER2-ultralow cohort ENHERTU and chemotherapy. Hazard ratio footnote a (unstratified) applies to the overall population, b (stratified) to the HER2-low cohort, and c to the response rates. The comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel. Patients had HR-positive disease that had progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease. PFS and ORR were assessed by blinded independent central review at the PFS final analysis.

<a id="enhertu-destiny-breast06-her2-ultralow"></a>

### How effective is Enhertu in HER2-ultralow breast cancer (DESTINY-Breast06)?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “In an exploratory analysis of the HER2-ultralow subgroup (n=153), median PFS 
> was 15.1 months (95% CI: 10.0, 17.3) in patients randomized to ENHERTU and 
> 8.3 months (95% CI: 5.8, 15.2) in patients randomized to chemotherapy with a 
> hazard ratio of 0.76 (95% CI: 0.49, 1.17). Confirmed ORR (BICR) was 65.7%  
> (95% CI: 53.1, 76.8) and 30.8% (95% CI: 19.9, 43.4) in patients randomized to  
> ENHERTU and chemotherapy and with measurable disease at baseline, respectively. 
> Median DOR was 14.3 months (95% CI: 11.8, not estimable) and 14.1 months  
> (95% CI: 5.9, not estimable) in patients randomized to ENHERTU and chemotherapy, 
> respectively.”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

> “The HER2-ultralow cohort was an exploratory population. The data are descriptive and were not tested for statistical significance, nor powered to show a difference between treatment arms. Therefore, the clinical significance of these data cannot be determined”

Source: [ENHERTU: Efficacy in HER2-low and HER2-ultralow mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low-and-her2-ultralow#:~:text=The%20HER2%2Dultralow%20cohort%20was%20an,these%20data%20cannot%20be%20determined)

Note: Exploratory subgroup of DESTINY-Breast06 (HR-positive, HER2-ultralow; ENHERTU n=77, chemotherapy n=76) at the PFS final analysis; patients had progressed on endocrine therapy in the metastatic setting without prior chemotherapy for metastatic disease. The comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel.

<a id="enhertu-destiny-breast06-overall-survival"></a>

### Does Enhertu help patients live longer in DESTINY-Breast06?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “At the time of the PFS final analysis, OS data were not yet mature<sup>1</sup>”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=At%20the%20time%20of%20the,OS%20data%20were%20not%20yet)

> “At the time of the PFS 
> final analysis, overall survival (OS) data was immature, and a total of 335 (39%)  
> of patients had died across both study arms in the overall population.”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

Note: DESTINY-Breast06: HR-positive HER2-low or HER2-ultralow metastatic breast cancer that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease; ENHERTU (N=436) vs physician's choice of capecitabine, nab-paclitaxel, or paclitaxel (N=430).

<a id="enhertu-destiny-breast06-time-to-response"></a>

### How quickly does Enhertu work in HER2-low breast cancer (DESTINY-Breast06)?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “Median time to response (TTR) was 2.7 months with ENHERTU and 2.6 months with chemotherapy<sup>4</sup>”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=Median%20time%20to%20response%20%28TTR%29,ENHERTU%20and%202.6%20months%20with)

> “DCR was 92% with ENHERTU (n=300/326) and 79.9% with chemotherapy (n=259/324)<sup>4</sup>”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=DCR%20was%2092%25%20with%20ENHERTU%20%28n%3D300%2F326%29%20and%2079.9%25%20with%20chemotherapy)

> “TTR and DCR were not tested for statistical significance and were not powered to show differences between treatment arms. Therefore, the clinical significance of these data cannot be determined”

Source: [ENHERTU: Efficacy in HR+/HER2-low mBC, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/efficacy/her2-low#:~:text=TTR%20and%20DCR%20were%20not,these%20data%20cannot%20be%20determined)

Note: HR-positive HER2-low cohort of DESTINY-Breast06 (after endocrine therapy, without prior chemotherapy for metastatic disease), patients with measurable disease at baseline, per Daiichi Sankyo data on file as cited on the source page; the comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel. DCR is disease control rate (complete response, partial response, or stable disease).

<a id="enhertu-destiny-breast04-overall-survival"></a>

### Does Enhertu improve survival vs chemotherapy in HR-positive HER2-low breast cancer (DESTINY-Breast04)?

Applies to: Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

> “Table 33: Efficacy Results in DESTINY-Breast04
> Efficacy 
> Parameter
> HR+ Cohort 
> Overall Population
> (HR+ and HR- Cohorts)
> ENHERTU
> (N=331)
> Chemotherapy
> (N=163)
> ENHERTU
> (N=373)
> Chemotherapy
> (N=184)”

Source: [ENHERTU: Prescribing information, page 22, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=22)

> “Overall Survival
> Number of 
> events (%)
> 126 (38.1)
> 73 (44.8)
> 149 (39.9)
> 90 (48.9)
> Median, months 
> (95% CI)
> 23.9  
> (20.8, 24.8)
> 17.5  
> (15.2, 22.4)
> 23.4  
> (20.0, 24.8)
> 16.8  
> (14.5, 20.0)
> Hazard ratio 
> (95% CI)
> 0.64 (0.48, 0.86)
> 0.64 (0.49, 0.84)
> p-value
> 0.0028
> 0.001”

Source: [ENHERTU: Prescribing information, page 22, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=22)

Note: Table 33 columns, in order: HR-positive cohort ENHERTU (N=331) and chemotherapy (N=163), then the overall population (HR-positive and HR-negative cohorts) ENHERTU (N=373) and chemotherapy (N=184). The HR-positive cohort columns apply to the indication covered here. Results are those of Prescribing Information Table 33. The comparator was physician's choice of eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel, in patients previously treated with chemotherapy for metastatic disease (or recurrence within 6 months of adjuvant chemotherapy). The first hazard ratio and p-value (0.64; 0.0028) are for the HR-positive cohort; the second (0.64; 0.001) are for the overall population.

<a id="enhertu-destiny-breast04-pfs"></a>

### How long is Enhertu PFS vs chemotherapy in HR-positive HER2-low breast cancer (DESTINY-Breast04)?

Applies to: Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

> “Table 33: Efficacy Results in DESTINY-Breast04
> Efficacy 
> Parameter
> HR+ Cohort 
> Overall Population
> (HR+ and HR- Cohorts)
> ENHERTU
> (N=331)
> Chemotherapy
> (N=163)
> ENHERTU
> (N=373)
> Chemotherapy
> (N=184)”

Source: [ENHERTU: Prescribing information, page 22, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=22)

> “Progression-Free Survival per BICR
> Number of 
> events (%)
> 211 (63.7)
> 110 (67.5)
> 243 (65.1)
> 127 (69.0)
> Median, months 
> (95% CI)
> 10.1  
> (9.5, 11.5)
> 5.4  
> (4.4, 7.1)
> 9.9  
> (9.0, 11.3)
> 5.1  
> (4.2, 6.8)
> Hazard ratio 
> (95% CI)
> 0.51 (0.40, 0.64)
> 0.50 (0.40, 0.63)
> p-value
> <0.0001
> <0.0001”

Source: [ENHERTU: Prescribing information, page 22, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=22)

Note: Table 33 columns, in order: HR-positive cohort ENHERTU (N=331) and chemotherapy (N=163), then the overall population (HR-positive and HR-negative cohorts) ENHERTU (N=373) and chemotherapy (N=184). The HR-positive cohort columns apply to the indication covered here. Results are those of Prescribing Information Table 33. The comparator was physician's choice of eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel, in patients previously treated with chemotherapy for metastatic disease (or recurrence within 6 months of adjuvant chemotherapy). PFS was assessed by blinded independent central review; PFS in the HR-positive cohort was the primary endpoint. The first hazard ratio (0.51) is for the HR-positive cohort; the second (0.50) is for the overall population.

<a id="enhertu-destiny-breast04-response"></a>

### What is the response rate with Enhertu in HR-positive HER2-low breast cancer (DESTINY-Breast04)?

Applies to: Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

> “Table 33: Efficacy Results in DESTINY-Breast04
> Efficacy 
> Parameter
> HR+ Cohort 
> Overall Population
> (HR+ and HR- Cohorts)
> ENHERTU
> (N=331)
> Chemotherapy
> (N=163)
> ENHERTU
> (N=373)
> Chemotherapy
> (N=184)”

Source: [ENHERTU: Prescribing information, page 22, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=22)

> “Confirmed Objective Response Rate per BICR
> n (%)
> 175 (52.9)
> 27 (16.6)
> 195 (52.3)
> 30 (16.3)
> 95% CI
> 47.3, 58.4
> 11.2, 23.2
> 47.1, 57.4
> 11.3, 22.5
> Complete 
> Response n (%)
> 12 (3.6)
> 1 (0.6)
> 13 (3.5)
> 2 (1.1)
> Partial Response 
> n (%)
> 164 (49.5)
> 26 (16.0)
> 183 (49.1)
> 28 (15.2)
> Duration of Response per BICR
> Median, months 
> (95% CI)
> 10.7  
> (8.5, 13.7)
> 6.8  
> (6.5, 9.9)
> 10.7  
> (8.5, 13.2)
> 6.8  
> (6.0, 9.9)”

Source: [ENHERTU: Prescribing information, page 22, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=22)

> “ORR and mDOR were not tested for statistical significance and were not powered to show differences between treatment arms. Therefore, the clinical significance of these data cannot be determined”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=ORR%20and%20mDOR%20were%20not,these%20data%20cannot%20be%20determined)

Note: Table 33 columns, in order: HR-positive cohort ENHERTU (N=331) and chemotherapy (N=163), then the overall population (HR-positive and HR-negative cohorts) ENHERTU (N=373) and chemotherapy (N=184). The HR-positive cohort columns apply to the indication covered here. Results are those of Prescribing Information Table 33. The comparator was physician's choice of eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel, in patients previously treated with chemotherapy for metastatic disease (or recurrence within 6 months of adjuvant chemotherapy). Confirmed objective response and duration of response were assessed by blinded independent central review; in each row the first value is the HR-positive cohort on ENHERTU and the second the HR-positive cohort on chemotherapy.

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/indication)
- [Safety](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/guidelines)
